Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
about
Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemPlasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsNeutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug TherapyProduction, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic VariationSeasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy.Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model.A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infectionBlood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates.Malaria vaccines and human immune responses.Immunomic approaches for antigen discovery of human parasites.Vaccines to Accelerate Malaria Elimination and Eventual Eradication.Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure.Controlled Human Malaria Infection: Applications, Advances and Challenges.Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach.A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Unraveling Haplotype Diversity of the Apical Membrane Antigen-1 Gene in Plasmodium falciparum Populations in Thailand.Plasmodium falciparum Liver Stage Infection and Transition to Stable Blood Stage Infection in Liver-Humanized and Blood-Humanized FRGN KO Mice Enables Testing of Blood Stage Inhibitory Antibodies (Reticulocyte-Binding Protein Homolog 5) In Vivo.Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cellsMalaria Vaccines: Recent Advances and New Horizons
P2860
Q26700012-C018498F-CAE3-4660-90D4-B049A7F65D18Q28066456-08DE8019-5AFF-4141-80CA-88E72DA4D83EQ28552661-DA838BAE-7602-40E7-A266-DBB8600773D4Q28554439-DA134369-2F48-427F-A0FF-5BFD7F746538Q30234589-7BC6459A-CD9B-4F9A-AABE-3D280DB9F46CQ33798074-23F2E36B-33EA-464C-8DD7-7CF4F1D7DD30Q33835382-A892B235-BF5C-4049-85EC-D144A257BC75Q37334935-7BC5786B-C393-49A1-9C7E-D8DD09F1BA7BQ38607982-81EAED21-C7D6-4A6E-AC97-AAB3EB4361E6Q38626558-48C0CB02-4C16-493F-8C68-73C4CC921E87Q38672088-C014E05A-1AB7-4E86-9450-C2638268447EQ38854831-6393EE9E-1889-48D2-9339-8B485D6EBDBFQ38989213-A3CE8E2A-06F1-4DCD-A526-FC7F6E82FB19Q39296506-69528D8F-094A-4449-9CC7-9B333216E02FQ40082198-69721B3E-4533-45CB-A73B-3C1C645FC6A0Q44168331-DC36FC5C-0FA1-4B52-9247-25E7DDE23CD7Q47106697-40235AB6-F2B6-4A2C-B23E-8F3B3F58CFECQ47111142-A6736A52-1DD8-4398-9C61-992BA0515680Q47547431-0902F66E-24F9-43CB-8F79-14094F41C0DFQ47576664-B9CEFEB9-5586-4982-A855-D0DF7E8EFCA4Q55008319-F3F376DF-36D8-4E32-9024-01B1E990ADBAQ55050933-5C41A5CB-421E-4339-BF6A-CC07A0333750Q56342201-85D082E5-A216-4563-8F96-911D7FF4530CQ56362064-F402B788-1B96-439D-BD93-88883B104AC6
P2860
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Demonstration of the Blood-Sta ...... Antigen 1 Vaccine, FMP2.1/AS01
@en
type
label
Demonstration of the Blood-Sta ...... Antigen 1 Vaccine, FMP2.1/AS01
@en
prefLabel
Demonstration of the Blood-Sta ...... Antigen 1 Vaccine, FMP2.1/AS01
@en
P2093
P2860
P50
P356
P1476
Demonstration of the Blood-Sta ...... Antigen 1 Vaccine, FMP2.1/AS01
@en
P2093
Alison M Lawrie
April K Kathcart
Ashley J Birkett
Aziz N Qabar
Carole A Long
Carter L Diggs
Christian F Ockenhouse
Colleen Woods
Fay L Nugent
Graham S Cooke
P2860
P304
P356
10.1093/INFDIS/JIW039
P407
P50
P577
2016-02-04T00:00:00Z